vs
Side-by-side financial comparison of Tonix Pharmaceuticals Holding Corp. (TNXP) and X3 Holdings Co., Ltd. (XTKG). Click either name above to swap in a different company.
Tonix Pharmaceuticals Holding Corp. is the larger business by last-quarter revenue ($5.4M vs $5.0M, roughly 1.1× X3 Holdings Co., Ltd.). X3 Holdings Co., Ltd. produced more free cash flow last quarter ($-1.7M vs $-41.5M).
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
TNXP vs XTKG — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $5.0M |
| Net Profit | $-46.9M | — |
| Gross Margin | 80.4% | — |
| Operating Margin | -895.8% | — |
| Net Margin | -870.3% | — |
| Revenue YoY | 108.8% | — |
| Net Profit YoY | -112.2% | — |
| EPS (diluted) | $-4.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.4M | — | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $2.0M | $5.0M | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.6M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $2.2M | $6.6M | ||
| Q1 24 | $2.5M | — |
| Q4 25 | $-46.9M | — | ||
| Q3 25 | $-32.0M | — | ||
| Q2 25 | $-28.3M | — | ||
| Q1 25 | $-16.8M | — | ||
| Q4 24 | $-22.1M | — | ||
| Q3 24 | $-14.2M | — | ||
| Q2 24 | $-78.8M | $-57.6M | ||
| Q1 24 | $-14.9M | — |
| Q4 25 | 80.4% | — | ||
| Q3 25 | 58.4% | — | ||
| Q2 25 | -63.8% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 54.2% | — | ||
| Q3 24 | 44.9% | — | ||
| Q2 24 | -52.5% | 28.0% | ||
| Q1 24 | 33.1% | — |
| Q4 25 | -895.8% | — | ||
| Q3 25 | -1005.1% | — | ||
| Q2 25 | -1416.2% | — | ||
| Q1 25 | -660.9% | — | ||
| Q4 24 | -870.6% | — | ||
| Q3 24 | -551.2% | — | ||
| Q2 24 | -3501.6% | -219.1% | ||
| Q1 24 | -860.2% | — |
| Q4 25 | -870.3% | — | ||
| Q3 25 | -972.9% | — | ||
| Q2 25 | -1415.0% | — | ||
| Q1 25 | -692.8% | — | ||
| Q4 24 | -856.2% | — | ||
| Q3 24 | -503.6% | — | ||
| Q2 24 | -3567.8% | -874.1% | ||
| Q1 24 | -601.9% | — |
| Q4 25 | $-4.28 | — | ||
| Q3 25 | $-3.59 | — | ||
| Q2 25 | $-3.86 | — | ||
| Q1 25 | $-2.84 | — | ||
| Q4 24 | $2302.65 | — | ||
| Q3 24 | $-22.68 | — | ||
| Q2 24 | $-1920.85 | — | ||
| Q1 24 | $-535.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.6M | $2.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $245.2M | $42.6M |
| Total Assets | $277.2M | $71.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $207.6M | — | ||
| Q3 25 | $190.1M | — | ||
| Q2 25 | $125.3M | $2.6M | ||
| Q1 25 | $131.7M | — | ||
| Q4 24 | $98.8M | — | ||
| Q3 24 | $28.2M | — | ||
| Q2 24 | $4.2M | $1.5M | ||
| Q1 24 | $7.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $10.1M | — | ||
| Q1 24 | $10.8M | — |
| Q4 25 | $245.2M | — | ||
| Q3 25 | $231.1M | — | ||
| Q2 25 | $168.0M | $42.6M | ||
| Q1 25 | $180.4M | — | ||
| Q4 24 | $139.6M | — | ||
| Q3 24 | $74.2M | — | ||
| Q2 24 | $42.1M | $125.5M | ||
| Q1 24 | $108.1M | — |
| Q4 25 | $277.2M | — | ||
| Q3 25 | $252.4M | — | ||
| Q2 25 | $187.4M | $71.7M | ||
| Q1 25 | $192.9M | — | ||
| Q4 24 | $162.9M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.3M | $171.3M | ||
| Q1 24 | $135.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-39.6M | $-1.1M |
| Free Cash FlowOCF − Capex | $-41.5M | $-1.7M |
| FCF MarginFCF / Revenue | -770.4% | -34.1% |
| Capex IntensityCapex / Revenue | 34.8% | 12.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-103.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-39.6M | — | ||
| Q3 25 | $-28.8M | — | ||
| Q2 25 | $-14.8M | $-1.1M | ||
| Q1 25 | $-16.6M | — | ||
| Q4 24 | $-14.6M | — | ||
| Q3 24 | $-18.8M | — | ||
| Q2 24 | $-9.9M | $-7.0M | ||
| Q1 24 | $-17.6M | — |
| Q4 25 | $-41.5M | — | ||
| Q3 25 | $-29.7M | — | ||
| Q2 25 | $-15.4M | $-1.7M | ||
| Q1 25 | $-16.6M | — | ||
| Q4 24 | $-14.6M | — | ||
| Q3 24 | $-18.8M | — | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | $-17.7M | — |
| Q4 25 | -770.4% | — | ||
| Q3 25 | -904.1% | — | ||
| Q2 25 | -768.8% | -34.1% | ||
| Q1 25 | -682.8% | — | ||
| Q4 24 | -566.7% | — | ||
| Q3 24 | -666.5% | — | ||
| Q2 24 | — | -106.9% | ||
| Q1 24 | -712.4% | — |
| Q4 25 | 34.8% | — | ||
| Q3 25 | 29.2% | — | ||
| Q2 25 | 26.4% | 12.1% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 4.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TNXP
| Zembrace Symtouch | $3.1M | 58% |
| Other | $2.3M | 42% |
XTKG
| Consulting and technical support services | $2.4M | 48% |
| Other | $1.5M | 30% |
| Application development services | $884.5K | 18% |
| Subscription services | $215.4K | 4% |
